Episurf Medical Receives CE Mark for Its Personalized Implants
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Episurf Medical Receives CE Certification for its Knee Implant and Prepares for Upcoming Product Launch
STOCKHOLM, July 4, 2013 /PRNewswire/ -- Episurf Medical received CE certification for its personalized implant, the Episealer® Femoral Condyle, which treats cartilage damage in the knee, restoring movement and reducing pain. CE certification is a prerequisite for the sale of medical devices in the European market.
(Photo: http://photos.prnewswire.com/prnh/20130704/626331 )
CE certification was obtained after the Episealer® Femoral Condyle and its technical documentation underwent review by regulatory authorities and successfully demonstrated that it met EU standards for medical equipment. CE certification means that Episurf Medical has the formal approval required to market and sell the product in the EU.
"The approval is an important milestone for the company, allowing us to launch products in Europe and bringing Episurf Medical into the first phase of commercialization. This new approval, in combination with a recent 70 million SEK rights issue and signed distribution contracts in Switzerland and Poland, puts us in a strong position for our product launch this fall." says Nina Bake, CEO of Episurf Medical.
As a first step Episealer® Femoral Condyle will be launched on the European market. To ensure high quality and to provide maximum safety for patients and surgeons, the launch will be rolled out in stages under controlled conditions to a limited number of qualified orthopedic clinics in strategically selected European countries. While this first phase is underway, Episurf will continue working to establish distribution contracts in other selected markets.
Episealer® Femoral Condyle is the company's first commercial product based on Episurf's unique patented technology, in which small personalized implants grow in the bone, fixing cartilage damage at an early stage, restoring movement and reducing pain. Several patients have already successfully received treatment with Episurf's implants in an ongoing clinical trial.
About Episurf Medical:
Episurf is dedicated to providing people with painful joint injuries a more active and healthy life by making available minimally invasive and tailored treatment options. Episurf Medical's personalized Episealer® implant and surgical drilling template Epiguide® were developed for the treatment of localized cartilage damage in joints. The implants are specifically designed to each patient's unique injury for optimum fit and minimal intervention.
Episurf is headquartered in Stockholm, Sweden. Shares (EPIS B) are listed on NASDAQ OMX First North. Certified Adviser: Wildeco Economic Information AB.
For more information, please contact:
Nina Bake, CEO Episurf Medical
Tel: +46(0)736-125-563
press@episurf.com
Help employers find you! Check out all the jobs and post your resume.
Episurf Medical Receives CE Certification for its Knee Implant and Prepares for Upcoming Product Launch
STOCKHOLM, July 4, 2013 /PRNewswire/ -- Episurf Medical received CE certification for its personalized implant, the Episealer® Femoral Condyle, which treats cartilage damage in the knee, restoring movement and reducing pain. CE certification is a prerequisite for the sale of medical devices in the European market.
(Photo: http://photos.prnewswire.com/prnh/20130704/626331 )
CE certification was obtained after the Episealer® Femoral Condyle and its technical documentation underwent review by regulatory authorities and successfully demonstrated that it met EU standards for medical equipment. CE certification means that Episurf Medical has the formal approval required to market and sell the product in the EU.
"The approval is an important milestone for the company, allowing us to launch products in Europe and bringing Episurf Medical into the first phase of commercialization. This new approval, in combination with a recent 70 million SEK rights issue and signed distribution contracts in Switzerland and Poland, puts us in a strong position for our product launch this fall." says Nina Bake, CEO of Episurf Medical.
As a first step Episealer® Femoral Condyle will be launched on the European market. To ensure high quality and to provide maximum safety for patients and surgeons, the launch will be rolled out in stages under controlled conditions to a limited number of qualified orthopedic clinics in strategically selected European countries. While this first phase is underway, Episurf will continue working to establish distribution contracts in other selected markets.
Episealer® Femoral Condyle is the company's first commercial product based on Episurf's unique patented technology, in which small personalized implants grow in the bone, fixing cartilage damage at an early stage, restoring movement and reducing pain. Several patients have already successfully received treatment with Episurf's implants in an ongoing clinical trial.
About Episurf Medical:
Episurf is dedicated to providing people with painful joint injuries a more active and healthy life by making available minimally invasive and tailored treatment options. Episurf Medical's personalized Episealer® implant and surgical drilling template Epiguide® were developed for the treatment of localized cartilage damage in joints. The implants are specifically designed to each patient's unique injury for optimum fit and minimal intervention.
Episurf is headquartered in Stockholm, Sweden. Shares (EPIS B) are listed on NASDAQ OMX First North. Certified Adviser: Wildeco Economic Information AB.
For more information, please contact:
Nina Bake, CEO Episurf Medical
Tel: +46(0)736-125-563
press@episurf.com
Help employers find you! Check out all the jobs and post your resume.